Literature DB >> 4017286

Depressed classical complement pathway activities in chronic lymphocytic leukaemia.

G Füst, E Czink, D Minh, Z Miszlay, L Varga, S R Hollán.   

Abstract

Haemolytic activities of the classical and alternative complement pathways, and levels of C1, C4, C3, factor B and C1 inhibitor (C1-INH) were measured in 85 serum samples from 46 patients with chronic lymphocytic leukaemia (CLL). Significantly decreased mean C1 and C4 levels were found, and the haemolytic activities of these components were low or low normal in more than 50% of the sera tested. In 15 sera from 5 patients a complement profile characteristic of acquired C1-IHN deficiency was observed. These results indicate that the depression of the activity of the classical complement pathway is a frequently occurring feature in CLL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4017286      PMCID: PMC1577204     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Acquired c1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases.

Authors:  G Hauptmann; J M Lang; M L North; F Oberling; G Mayer; P Lachmann
Journal:  Blut       Date:  1976-03

2.  Functionally active C1 on the surface of human peripheral lymphocytes: its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes.

Authors:  G Füst; A Erdei; G Sármay; G A Medgyesi; J Gergely
Journal:  Clin Immunol Immunopathol       Date:  1976-05

3.  Activation of the alternate pathway of human complements by rabbit cells.

Authors:  T A Platts-Mills; K Ishizaka
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

4.  Serum complement level in patients with leukemia.

Authors:  S Yoshikawa; K Yamada; T O Yoshida
Journal:  Int J Cancer       Date:  1969-11-15       Impact factor: 7.396

5.  [Acquired C1-esterase inhibitor deficiencies during lymphoid syndromes].

Authors:  F Oberling; G Hauptmann; J M Lang; J P Bergerat; G Mayer; A Batzenschlager; B Hammann; B Gillet
Journal:  Nouv Presse Med       Date:  1975-11-08

6.  Letter: C1-esterase inactivators and C4 in malignant diseases.

Authors:  N Bach-Martensen; K Osther; I Stroyer
Journal:  Lancet       Date:  1975-09-13       Impact factor: 79.321

7.  The presence of active C1 (C-1) on peripheral human lymphocytes.

Authors:  H Kitamura; H Teshima; N K Day
Journal:  Vox Sang       Date:  1978       Impact factor: 2.144

8.  Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality.

Authors:  A D Schreiber; B Zweiman; P Atkins; F Goldwein; G Pietra; B Atkinson; N I Abdou
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

9.  Detection of circulating immune complexes in pathological human sera.

Authors:  A H Johnson; J F Mowbray; K A Porter
Journal:  Lancet       Date:  1975-04-05       Impact factor: 79.321

10.  Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL).

Authors:  N K Day; J B Winfield; T Gee; R Winchester; H Teshima; H G Kunkel
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

View more
  13 in total

Review 1.  Complement System: a Neglected Pathway in Immunotherapy.

Authors:  Anne Bordron; Cristina Bagacean; Adrian Tempescul; Christian Berthou; Eléonore Bettacchioli; Sophie Hillion; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

Review 2.  Aspects of C1-inhibitor biochemistry and pathophysiology.

Authors:  T K Nilsson
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

3.  Acquired C1 inhibitor deficiency associated with systemic lupus erythematosus affecting the central nervous system.

Authors:  S Nakamura; M Yoshinari; Y Saku; K Hirakawa; C Miishima; K Murai; K Tokiyama; M Fujishima
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

Review 4.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

5.  Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia.

Authors:  L Varga; E Czink; Z Miszlai; K Pálóczi; A Bányai; G Szegedi; G Füst
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

6.  Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL.

Authors:  O Middleton; E Cosimo; E Dobbin; A M McCaig; C Clarke; A M Brant; M T Leach; A M Michie; H Wheadon
Journal:  Leukemia       Date:  2014-05-02       Impact factor: 11.528

7.  Rituximab for the treatment of patients with chronic lymphocytic leukemia.

Authors:  M Gentile; E Vigna; C Mazzone; E Lucia; Ag Recchia; L Morabito; Mg Bisconte; C Gentile; F Morabito
Journal:  Cancer Manag Res       Date:  2010-03-11       Impact factor: 3.989

8.  Unexpected etiology of a pleural empyema in a patient with chronic lymphocytic leukemia (CLL): Capnocytophaga ochracea.

Authors:  Samantha A Basco; Gregory M Steele; Andrés F Henao-Martínez; Carlos Franco-Paredes; Daniel B Chastain
Journal:  IDCases       Date:  2020-03-20

9.  A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.

Authors:  Regina Michelis; Tamar Tadmor; Masad Barhoum; Mona Shehadeh; Lev Shvidel; Ariel Aviv; Galia Stemer; Najib Dally; Naomi Rahimi-Levene; Mona Yuklea; Andrei Braester
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

Review 10.  How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application.

Authors:  Shanshan Luo; Moran Wang; Huafang Wang; Desheng Hu; Peter F Zipfel; Yu Hu
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.